Latest news with #cancerresearch
Yahoo
5 hours ago
- Sport
- Yahoo
Cubs players to wear blue No. 23 jerseys in honor of Ryne Sandberg against Orioles on Saturday
The Chicago Cubs will pay tribute to franchise legend Ryne Sandberg on Saturday, days after the Hall of Famer died following a battle with cancer. Crane Kenney, the team's President of Business Operations, told 670 The Score in Chicago that the Cubs will wear blue jerseys on Saturday against the Baltimore Orioles — their first home game since Sandberg's death — with every player sporting No. 23, Sandberg's number, and no names on the back. The jerseys will then be auctioned off postgame with proceeds benefiting cancer research as part of Cubs For A Cure. "The whole day will be Ryno's day on Saturday," Kenney said. The day after Sandberg's death was announced the Cubs debuted a special jersey patch that they will wear for the remainder of the season. The blue patch on the left shoulder features Sandberg's No. 23 and his signature. Sandberg, who was 65, was inducted into the Baseball Hall of Fame in 2005. He played all but 13 games of his 16-season MLB career with the Cubs. He joined the majors in a brief stint with the Philadelphia Phillies in 1981 and was traded the following offseason to Chicago. He became a full-time starter in his first season with the Cubs in 1982 and made the first of 10 straight All-Star appearances in 1984 — a season where he would claim NL MVP. It was revealed in January 2024 that Sandberg had been diagnosed with metastatic prostate cancer. Last July, he informed fans that scans had shown no signs of cancer and he later rang the bell, signaling that his body was cancer-free after an eight-month battle. This past December, Sandberg revealed that the cancer had returned and spread to other organs in his body. A beloved Cub known on the field for his production and reliability, Sandberg played in at least 115 games in 14 of his 15 seasons in Chicago. He played in fewer than 150 games just four times. In June, the Cubs unveiled a statue of Sandberg outside of Wrigley Field.
Times
4 days ago
- Health
- Times
Scientists' discovery could stop breast cancer spreading
Scottish scientists have made a discovery that could help stop breast cancer spreading to other parts of the body. Experts at Cancer Research UK Scotland Institute and the University of Glasgow have found there are key metabolic changes that take place before tumours grow elsewhere. Their work is being hailed as a significant breakthrough because it is often cancer moving from the breast that kills patients. • How I told my sons that I had a rare form of breast cancer Researchers writing in the journal EMBO Reports said identifying the metabolic changes offered a vital window to intervene. Detecting these changes early could allow therapies to stop cancer cells moving around the body and forming tumours elsewhere. Dr Cassie Clarke, lead researcher, said: 'This study represents a major shift in how we think about preventing the spread of breast cancer. By targeting these metabolic changes as early as possible we could stop the cancer progressing and save lives.' About 56,800 people are diagnosed with breast cancer in the United Kingdom each year and 11,300 people lose their lives to the disease. Dr Catherine Elliott, Cancer Research UK's director of research, said: 'Discoveries in cancer research have made huge strides in making breast cancer a far more treatable disease than ever before. • Why the way we diagnose, label and treat cancer is changing 'However, metastasis — when cancer spreads — is a major factor in breast cancer becoming harder to treat, especially if the cancer returns months or even many years later. 'This discovery gives us new hope for detecting and stopping metastasis early and ensuring people have many more years with their families and loved ones.' The study focused on how breast cancer changes the immune system so it cannot tackle cancer cells as they begin their spread. The researchers found that cancer changes the metabolism — the way cells make and use energy — of specific immune cells, resulting in them releasing a prominent metabolite called uracil. Uracil is a molecule key to essential processes in the body which was found to help distant organs build a 'scaffold' to grow secondary tumours elsewhere in the body. By blocking an enzyme called uridine phosphorylase-1 (UPP1), which produces uracil, the scientists were able to stop this scaffold forming in mice and restore the ability of the immune system to kill secondary cancer cells to prevent metastasis. This opens the door to potentially powerful new tools to tackle cancer. Detecting uracil in the blood could help spot early signs of cancer spread, while blocking UPP1 with drugs could stop the spread before it starts. • The Times View: It is time to be optimistic about cancer The research was funded by Cancer Research UK, the Wellcome Trust, the Medical Research Council, Breast Cancer Now and Pancreatic Cancer UK. Simon Vincent, chief scientific officer at Breast Cancer Now, said: 'The researchers discovered that high levels of a protein called UPP1 may make some cancers, including breast cancer, more likely to spread to other parts of the body, where the disease becomes incurable. 'In mice, targeting the UPP1 protein before secondary breast cancer developed led to fewer secondary breast tumours and a boosted immune response in the lungs. 'Now we need more research to see if this new insight can be turned into new drugs that stop secondary breast cancer, and potentially other secondary cancers, in their tracks. With around 61,000 people living with secondary breast cancer in the UK, research like this is vital.' The team are further investigating exactly how UPP1 changes the behaviour of immune cells, exploring the role of immune cell metabolism in early breast cancer initiation, and testing the ability of drugs that block immune cell metabolism to prevent cancer occurring.
BBC News
5 days ago
- Entertainment
- BBC News
Warwickshire fundraiser Mr Ovary given British Citizen's Award
A man who dresses as a giant ovary to raise awareness and funds for ovarian cancer research has been honoured with an award for services to healthcare. Craig McMurrough, from Stratford-upon-Avon, Warwickshire, has completed more than 200 runs and events, including the London Marathon and Great North Run, wearing a giant foam ovary costume. He took up the challenge after his sister Cheryl died with ovarian cancer in 2016. "It's a beautiful tribute to my late sister," said Mr McMurrough of the was among 27 people given the British Citizen Award (BCA) at the Palace of Westminster on Thursday for their outstanding contributions to society. Mr McMurrough has raised close to £100,000 for cancer support charity Ovacome, and also created a choir for women with ovarian cancer."It feels wonderful to be awarded," he said. "It's a beautiful tribute to my late sister but also to all those other women we've lost to this terrible disease and those who continue to battle it," said Mr McMurrough. "Cheryl was simply an earth angel," he added. "She had the most caring, loving personality and everyone loved her - she did so much for others and was completely selfless, her bright blue eyes lit up a room and her infectious laugh meant you couldn't help but laugh and smile along with her."He said he hoped the award would give him the opportunity to spread awareness to an even wider audience."Cheryl's motto in life was never, never give up and I will continue to honour her memory every time I put my costume on," he said. Stephanie Wood from BCA partner One Stop said: "This year's medallists exemplify the incredible support within our communities, especially during challenging times."We're honoured to partner with the BCA and play a part in recognising these exceptional individuals." Follow BBC Coventry & Warwickshire on BBC Sounds, Facebook, X and Instagram.
CTV News
6 days ago
- Health
- CTV News
Hundreds of cyclists set for Cypress Mountain trek to raise pancreatic cancer awareness
Anthony Thomas and his wife Carolyn are among the hundreds of cyclists tackling the Cypress Challenge this weekend to raise money for cancer research. Some 800 cyclists are preparing to trek up Cypress Mountain to raise money for pancreatic cancer research and care this weekend. For 18 years, the Cypress Challenge has taken place in West Vancouver and is said to have grown into the largest privately funded fundraising event for pancreatic cancer in Canada. On Sunday, dozens of teams will embark on the 12 km. journey up the steep terrain in an attempt to add to the more than $5.2 million raised over the years. The BC Cancer Foundation estimates around 800 British Columbians will be diagnosed with pancreatic cancer this year, and it's projected that only 10 per cent of them will live another five years after that. West Vancouver resident and cyclist Anthony Thomas was diagnosed with the disease on Labour Day last year. Thomas explained to CTV News on Friday that he began feeling a sharp pain in his lower back while on a road trip back from B.C.'s Interior and was struck with nausea and felt ill. His wife Carolyn urged him to pull over and find care in Whistler, where they rushed to the emergency department. Thomas explained that after receiving tests, they found he had kidney stones, but also discovered masses on his pancreas and liver. After an MRI he was diagnosed with pancreatic cancer. 'It's been a challenging year, for sure, because I felt completely normal and fine,' said Thomas. He was diagnosed with neuroendocrine pancreatic cancer, a form he was told is rare but manageable. 'It's still bad, it's pancreatic cancer, but there are much better chances of getting through it,' said Thomas. 'When I found that out I really felt like I'd won the lottery.' Since the diagnosis, Thomas and his family have raised more than $50,000 for pancreatic cancer research and are looking to grow that number this weekend during the Cypress Challenge. Donations can be made on the Cypress Challenge website.
Globe and Mail
6 days ago
- Business
- Globe and Mail
AstraZeneca's Innovative Cancer Study: A Potential Game-Changer?
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca's ongoing study, titled 'A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)', aims to evaluate the safety and effectiveness of AZD9574, alone and with other anti-cancer drugs, in patients with advanced cancers. The study tests AZD9574, an experimental drug, both as a standalone treatment and in combination with other drugs like Temozolomide, Trastuzumab Deruxtecan, and Datopotamab Deruxtecan. These interventions target various advanced solid tumors, including breast, ovarian, pancreatic, and prostate cancers. This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused. The study is designed to escalate doses to determine safety and efficacy. Key dates for the study include its start on June 24, 2022, with the latest update submitted on July 23, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates for stakeholders. The study's progress could influence AstraZeneca's stock performance and investor sentiment, especially if the results show promising efficacy. As the study involves novel cancer treatments, it could impact the competitive landscape in oncology, potentially affecting other companies in the sector. The study is currently recruiting, with further details available on the ClinicalTrials portal.
